Additionally, small-molecule drug predictions have provided us with new insights into the pathogenesis of ulcerative colitis, particularly targeting the abnormal activation of the sympathetic nervous system, with SLC3A2 potentially serving as a new molecular target. The gene discussed is SLC3A2; the disease is ulcerative colitis.